Search
Breakthrough Expansion Technology for Human γδT17 Cells
Online InquiryγδT17 cells are a specialized subpopulation of lymphocytes that share the characteristics of γδ T cells and Th17 cells, hence the name γδT17 cells. This cell plays an important role in the immune response, especially in the pathogenesis of inflammatory and autoimmune diseases. A recent study has proposed a novel method for in vitro polarization and expansion of human γδT17 cells from peripheral blood mononuclear cells (PBMCs), which provides new perspectives for further research and clinical applications.
By optimizing culture conditions, Creative Biolabs enables γδ T cells expansion, providing a robust and sustainable source of these potent immune cells. You can click to learn more about our related services.
| Services | What We Do | Advantages |
|---|---|---|
| γδ T Cell Isolation Services | Creative Biolabs is committed to offering comprehensive, one-stop γδ T cell isolation services from fresh or previously frozen PBMCs. We also offer custom services to support γδ T cell isolation from other samples such as murine and human skin as well as small intestinal intraepithelial lymphocytes. |
|
| γδ T Cell Activation and Expansion Services | Our scientists are very skilled in the research of γδ T cell activation and expansion and can offer a great diversity of in vitro or in vivo solutions, including a customized solution for γδ T cell activation and expansion. |
|
| γδ T Cell Characterization Services | We provide characterization services including, but not limited to, antibody analysis of γδ T cell immunophenotypes, morphological observations, phagocytosis testing, cytotoxicity assays, and CAR transduction of engineered γδ T cells. |
|
| γδ T Cell Production Services | Creative Biolabs has built a standard large-scale manufacturing process. We used cell culturing bags and a GMP-compliant cell separation system that allowed us to handle a higher number of γδ T cells. |
|
Understanding γδT17 Cells
Human and mouse γδ T cells act as a bridge between innate and adaptive immunity and are found mainly in the skin and mucous membranes as well as in the peripheral blood. They are classified into different subtypes according to TCR chain and cytokine production, with γδT1 cells mainly producing IFN-γ and γδT17 cells mainly producing IL-17. In humans, the majority of peripheral blood γδ T cells are the Vδ2 T cells of IFN-γ-producing cells, whereas γδT17 cells are relatively scarce, and the mechanisms of their differentiation and expansion are not clear.
γδT17 cells play a pivotal role in immune surveillance and host defense mechanisms, particularly at barrier surfaces such as the skin, gut, and lungs. They contribute to the maintenance of tissue homeostasis, protection against microbial pathogens, and modulation of inflammatory responses. Importantly, γδT17 cells exhibit potent anti-tumor activities, making them attractive targets for cancer immunotherapy.
Fig. 1 Migratory dynamics of γδT17 cells.1
The Breakthrough Expansion Technology
Despite the great therapeutic potential, it is difficult to expand γδT17 cells ex vivo to obtain sufficient numbers for therapeutic applications. Conventional T cell expansion methods, such as stimulation with anti-CD3 antibodies and interleukins, have had limited success in promoting γδT17 cell proliferation. Major problems include:
- Expansion of γδT17 cells usually results in the simultaneous expansion of other γδ T cell subsets, leading to a decrease in the purity and function of the desired cell population.
Recognizing the urgent need for improved amplification methods for γδT17 cells, a team of researchers has developed a breakthrough amplification technique tailored specifically for human γδT17 cells.
Fig. 2 Human γδT17 expansion in vitro from PBMCs.2
- This experimental method utilizes PBMCs as starting materials, and such cells are easily accessible from blood samples for experimental manipulation.
- The expansion and polarization of γδT17 cells were promoted by the combined use of IL-7 and γδ TCR.
- By analyzing IL-17A production, the polarization and functional status of γδT17 cells can be effectively assessed, providing an important tool for studying their role in the immune response.
Key features of this amplification technique include:
- Selective Expansion: Central to the success of this technology is its ability to selectively expand γδT17 cells while minimizing the expansion of unwanted cell populations.
- Scalable and Reproducible: Simplified protocols and standardized culture conditions facilitate seamless integration into the manufacturing process of cell-based therapies, providing a practical solution for large-scale production of therapeutic γδT17 cells.
Potential Applications
The application of breakthrough expansion technologies for human γδT17 cells holds great promise in a range of clinical settings, including cancer immunotherapy, infectious diseases and autoimmune disorders.
-
Immunotherapy Development
The expansion of specific γδT17 cells can provide the basis for the development of novel immunotherapies against infectious diseases, autoimmune diseases and tumors. -
Cancer Therapy
In the field of cancer immunotherapy, γδT17 cells offer a unique opportunity to target solid tumors with an immunosuppressive microenvironment. By exploiting their pro-inflammatory properties and tissue homing ability, γδT17 cells can infiltrate tumor tissues, exert cytotoxic effects on malignant cells, and stimulate anti-tumor immune responses. This approach may help in the development of new cancer treatment strategies. -
Vaccine Development
In the context of infectious diseases, γδT17 cells play a key role in host defense against pathogens by promoting the recruitment of immune effectors and the production of antimicrobial mediators. Utilizing the unique immune properties of these cells could facilitate the development of vaccines against specific pathogens and improve vaccine efficacy.
Creative Biolabs is leading the development of transformative technologies designed to unlock the full therapeutic potential of γδT17 cells. We are committed to driving innovation and advancing the frontiers of γδT17 cell immunotherapy. Future efforts will focus on refining scale-up technologies, optimizing manufacturing processes and exploring synergistic combinations with other immunotherapy modalities to maximize therapeutic efficacy.
References
- McKenzie, Duncan R., et al. "The emerging complexity of γδT17 cells." Frontiers in immunology 9 (2018): 363000.
- Chen, Xu, et al. "Expansion and Polarization of Human γδT17 Cells in vitro from Peripheral Blood Mononuclear Cells." Bio-protocol 14.1 (2024).
